Candidate vaccines against infectious agents and non-communicable diseases consist of purified proteins or proteins conjugated to synthetic peptides, or haptens, and use adjuvants or novel delivery platforms. Despite pre-clinical proof of concept, vaccine clinical efficacy is often limited to a small subset of immunized subjects. Additionally, very few adjuvants meet regulatory approval. Thus, more effective immunization strategies are needed. This lab focuses on novel immunization approaches that guide B and T cell lymphocytes toward generation of effective antibody (Ab) responses.